Axsome Therapeutics, Inc. (NasdaqGM: AXSM)
Health Care · Pharmaceuticals · US
$170.08
-1.67% today · +45.8% 1Y
Axsome Therapeutics, Inc. (NasdaqGM: AXSM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $9.06B and employs 1,346 people.
Over the last twelve months the share price has gained 45.8%, trading between 117.30 and 260.19.
Tweenvest scores Axsome Therapeutics, Inc. across four factors: quality 43/100, value 85/100. Its strongest factor is value.
AXSM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.06B
- Revenue (TTM)
- $776.57M
- P/E
- —
- EPS
- -3.76
- Dividend yield
- —
- Beta (5Y)
- 0.85
- 52-week high
- $260.19
- 52-week low
- $117.30
- Avg volume (3M)
- —
- Shares outstanding
- 52.38M
- Employees
- 1,346
- Next earnings
- —
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
- ISIN
- US05464T1043
- Founded
- 2012
- Listed since
- Nov 19, 2015
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Asymchem Laboratories (Tianjin) Co., Ltd.SZSE: 002821 | $9.93B | CN¥188.62 | +5.79% |
| CSPC Innovation Pharmaceutical Co., Ltd.SZSE: 300765 | $9.80B | CN¥47.19 | +6.89% |
| Sichuan Kelun Pharmaceutical Co., Ltd.SZSE: 002422 | $9.69B | CN¥40.85 | +5.12% |
| Lupin LimitedBSE: 500257 | $9.64B | Rs2,029.00 | -2.92% |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd.SHSE: 600196 | $8.79B | CN¥24.02 | +5.17% |
| Krka, d. d.LJSE: KRKG | $8.73B | €257.50 | -0.19% |
| Financière de Tubize SAENXTBR: TUB | $8.51B | €170.80 | +0.65% |
| Eisai Co., Ltd.TSE: 4523 | $8.27B | ¥4,640.00 | -0.77% |
Figures last refreshed Oct 4, 2026.